Results 11 to 20 of about 26,835 (181)

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real-world study. [PDF]

Int J Cancer
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Tang X, Sun JJ, Wan Z, Jing XY, Guo X, Gao J.   +5 more
europepmc   +2 more sources

CRAF R391W is a melanoma driver oncogene. [PDF]

, 2016
Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known.
Atefi, Mohammad, Avramis, Earl, Chmielowski, Bartosz, Friedman, Michael, Graeber, Thomas G, Lassen, Amanda, Le, Allison, Lomova, Anastasia, Ng, Charles, Ribas, Antoni, Titz, Bjoern, Tsoi, Jennifer   +11 more
core   +7 more sources

Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity

Frontiers in Oncology, 2022
The BRAF inhibitor vemurafenib, approved for treating patients with BRAF V600E-mutant and unresectable or metastatic melanomas, rapidly induces cutaneous adverse events, including hyperkeratotic skin lesions and cutaneous squamous cell carcinomas (cSCC).
Marius Tham, Hans-Jürgen Stark, Anna Jauch, Catherine Harwood, Catherine Harwood, Elizabeth Pavez Lorie, Petra Boukamp, Petra Boukamp   +7 more
doaj   +1 more source

Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma

BMC Health Services Research, 2023
Background Immune checkpoint inhibitors (ICIs) and targeted treatments have improved the health outcomes of patients with advanced melanoma. However, due to the high cost of novel therapies, it is crucial to evaluate their value by considering both ...
Si Ni Li, Xiaomin Wan, Liu Bao Peng, Ya Min Li, Jian He Li   +4 more
doaj   +1 more source

The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B

Frontiers in Pharmacology, 2021
Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but the frequent emergence of drug resistance remains a challenge.
Shi-Long Jiang, Shi-Long Jiang, Zhi-Bin Wang, Zhi-Bin Wang, Tao Zhu, Tao Zhu, Ting Jiang, Jiang-Feng Fei, Chong Liu, Chong Liu, Chao Luo, Chao Luo, Yan Cheng, Zhao-Qian Liu, Zhao-Qian Liu   +14 more
doaj   +1 more source

PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas

Cancer Biology & Medicine, 2022
Objective: The BRAF inhibitor, vemurafenib, has been widely used in the treatment of patients with melanoma-bearing BRAFV600E mutations. While the initial response to vemurafenib is usually excellent, the majority of patients eventually develop ...
Junling Shen, Jilong Yang, Lei Sang, Rui Sun, Weiyu Bai, Chao Wang, Yan Sun, Jianwei Sun   +7 more
doaj   +1 more source

Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection. [PDF]

PLoS ONE, 2015
We have previously demonstrated an impact of the BRAF inhibitor vemurafenib on patient lymphocyte counts. In the current study, the extent to which concomitant use of corticosteroids in BRAF inhibitor treated patients affects lymphocyte counts and ...
Wiebke Sondermann, Klaus G Griewank, Bastian Schilling, Elisabeth Livingstone, Julia C Leyh, Natalia Rompoti, Ioana Cosgarea, Tobias Schimming, Dirk Schadendorf, Lisa Zimmer, Uwe Hillen   +10 more
doaj   +1 more source

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. [PDF]

, 2019
BackgroundThis pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.MethodsThe data were pooled from BRIM-2 ...
Ascierto, Paolo A, Dréno, Brigitte, Flaherty, Keith T, Hauschild, Axel, Larkin, James, Lewis, Karl D, McArthur, Grant A, McKenna, Edward, Mun, Yong, Ribas, Antoni, Wongchenko, Matthew, Yan, Yibing, Zhu, Qian   +12 more
core   +2 more sources

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib

Cell Death and Disease, 2022
The use of the BRAF inhibitor vemurafenib exhibits drug resistance in the treatment of thyroid cancer (TC), and finding more effective multitarget combination therapies may be an important solution.
Linfei Hu, Jun Zhang, Mengran Tian, Ning Kang, Guangwei Xu, Jingtai Zhi, Xianhui Ruan, Xiukun Hou, Wei Zhang, Jiaoyu Yi, Weike Ma, Luchen Chang, Tao Tang, Xiangqian Zheng, Xi Wei, Ming Gao   +15 more
doaj   +1 more source

Vemurafenib Inhibits Acute and Chronic Enterovirus Infection by Affecting Cellular Kinase Phosphatidylinositol 4-Kinase Type IIIβ

Microbiology Spectrum, 2023
Enteroviruses are one of the most abundant viruses causing mild to serious acute infections in humans and also contributing to chronic diseases like type 1 diabetes. Presently, there are no approved antiviral drugs against enteroviruses. Here, we studied
Mira Laajala, Marleen Zwaagstra, Mari Martikainen, Magloire Pandoua Nekoua, Mehdi Benkahla, Famara Sane, Emily Gervais, Grace Campagnola, Anni Honkimaa, Amir-Babak Sioofy-Khojine, Heikki Hyöty, Ravi Ojha, Marie Bailliot, Giuseppe Balistreri, Olve Peersen, Didier Hober, Frank Van Kuppeveld, Varpu Marjomäki   +17 more
doaj   +1 more source